Yes, the main issue around the reduction of revenue is because when research is suspended it means that much of our revenue also gets suspended. We do a large amount of clinical research, clinical trials, funded by external industry, pharmaceutical companies and biotech companies. Because of what the hospitals have done to prepare for COVID-19, as you heard from the other witnesses, a large number of those clinical trials have been stopped. That revenue has also been stopped.
For us alone, our single institution, that represents a drop of over $6 million per month in revenue.